Eldar-Finkelman’s research is focused on the signal transduction field and drug development targeting protein kinases. She is well known for her pioneering work on the functions of GSK-3 and its contribution to diabetes and other pathogenies, including depressive behavior Alzheimer’s disease, and Huntington’s disease. Novel findings also include the unique evolution of GSK-3 isozymes. Eldar-Finkelman is a leading figure in developing novel substrate competitive inhibitors (SCIs) for GSK-3 with significant benefits as drug candidates.
פרופ' חגית אלדר-פינקלמן
סגל אקדמי בכיר בגנטיקה מולקולרית של אדם וביוכימיה
ממלא מקום חבר ועדת המינויים האוניברסיטאית בדיקאנט ומנהל הפקולטה לרפואה
גנטיקה מולקולרית של אדם וביוכימיה
סגל אקדמי בכיר
ממלא מקום חבר ועדת המינויים האוניברסיטאית בדיקאנט ומנהל הפקולטה לרפואה
דואר אלקטרוני: heldar@tauex.tau.ac.il
טלפון פנימי: 03-6405307
טלפון נוסף: 03-6405308
פקס: 03-6408749
משרד: רפואה-סאקלר, 1012
מידע כללי
Biography
Education
| 1994 – 1998 | Postdoctoral work with Nobel Laureate Professor Edwin G Krebs | School of Medicine, University of Washington (UW) |
| 1993 | Doctor of Philosophy (Ph.D.), Life Science | Weizmann Institute of Science |
| 1988 | Recipient of the British Council Award to conduct research in biological nuclear magnetic resonance | University of Oxford |
| 1988 | M.Sc., Chemsitry | Weizmann Institute of Science |
| 1982 | B.Sc., Chemistry | The Hebrew University |
Research
Eldar-Finkelman’s research is focused on the signal transduction field and drug development targeting protein kinases. She is well known for her pioneering work on the functions of GSK-3 and its contribution to diabetes and other pathogenies, including depressive behavior Alzheimer’s disease, and Huntington’s disease. Novel findings also include the unique evolution of GSK-3 isozymes. Eldar-Finkelman is a leading figure in developing novel substrate competitive inhibitors (SCIs) for GSK-3 with significant benefits as drug candidates.
The research in Eldar-Finkelman’s laboratory is focused on the development of new innovative therapeutics addressing unmet needs in the cancer neurodegenerative disorders arena. A particular interest is given to the protein kinases such as glycogen synthase kinase-3 (GSK-3), and ABL1 as prominent drug targets. We combine expertise in chemistry, biology, and computational modeling to design drugs with unique inhibition /modality. Our goal is to ultimately produce beneficial therapeutics for clinical practice.
Publications and Grants
Arciniegas Ruiz, S., Eldar-Finkelman, H. (2022) GSK-3 inhibitors: preclinical and clinical focus
on CNS- A decade onward. Front. Mol. Neurosci. 4:32.
Eldar-Finkelman H, Rippin, I. (2021) Mechanisms and therapeutic implications of GSK-3 in treating Neurodegeneration. Cells, 10(2): 262.
Rippin, I., Boner, K., Joseph, S., Sarsor, A., Vaks, L., Eldar-Finkelman, H. (2021) Inhibition of GSK-3 ameliorates the pathogenesis of Huntington's disases. Neurobiology of Disease, 154, 105336.
Rippin, I., Khazanov, N., Ben Joseph, S., Kudinov, T., Berent, E., Arciniegas Ruiz, S-M., Marciano, D., Levy, L., Gruzman, A., Senderowitz, Eldar-Finkelman, H. (2021) Discovery and design of novel small molecule GSK-3 inhibitors targeting the substrate binding site. (IJMS, 21: 8709.
Avrahami, L., Paz, R., Dominko, Silva Hecimovic, S., Bucci, C., Eldar-Finkelman, H. (2020) GSK-3-TSC axis governs lysosomal acidification through autophagy and endocytic pathways. Cell. Signal. 71: 109597.
Pardo, M., Cheng, Y., Velmeshe, D., Magistri, M., Eldar-Finkelman, H., Martinez, A., Faghihi, M.A., Jope, R.S., Beurel,E. (2017) Intranasal siRNA administration reveals IGF2 deficiency contributes to impaired cognition in Fragile X syndrome mice. JCI Insight 2:e91782.
Licht-Murava, A., Paz, R., Vaks L., Avrahami, L., Plotkin,B., Eisenstein, M., Eldar-Finkelman,H. (2016) A unique type of GSK-3 inhibitor brings new opportunities to the clinic. Sci Signal, 9(454), ra110.
